Literature DB >> 330395

Humoral immune response to the heat-labile enterotoxin of Escherichia coli in naturally acquired diarrhea and antitoxin determination by passive immune hemolysis.

D J Evans, G Ruiz-Palacios, D E Evans, H L DuPont, L K Pickering, J Olarte.   

Abstract

Acute- and convalescent-phase sera from 132 students attending a university in rural Mexico were assayed for antibody against the heat-labile enterotoxin (LT) of Escherichia coli by neutralization of LT activity in the Y-1 adrenal cell assay and by passive immune hemolysis of LT-sensitized sheep erythrocytes. The two titration methods produced comparable results with respect to antitoxin responses detected. An inverse relationship was found between acute geometric mean antitoxin titer and the occurrence of diarrhea associated with LT-producing E. coli, especially in newly arrived students from the U.S.A. A significant correlation (P less than 0.00 5) was found between a rise in antitoxin titer detectable by the passive immune hemolysis technique and diarrhea with LT-producing E. coli isolated. Thus, humoral antitoxin titers appear to be a useful indicator of immune status with respect to enterotoxigenic (LT) E. coli diarrhea.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 330395      PMCID: PMC421030          DOI: 10.1128/iai.16.3.781-788.1977

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  16 in total

1.  Travelers' diarrhea and toxigenic Escherichia coli.

Authors:  S L Gorbach; B H Kean; D G Evans; D J Evans; D Bessudo
Journal:  N Engl J Med       Date:  1975-05-01       Impact factor: 91.245

2.  Comparative susceptibility of latin american and united states students to enteric pathogens.

Authors:  H L DuPont; J Olarte; D G Evans; L K Pickering; E Galindo; D J Evans
Journal:  N Engl J Med       Date:  1976-12-30       Impact factor: 91.245

3.  Immunologic cross-reactions of enterotoxins from Escherichia coli and Vibrio cholerae.

Authors:  N W Smith; R B Sack
Journal:  J Infect Dis       Date:  1973-02       Impact factor: 5.226

4.  Antibodies to heat-labile Escherichia coli enterotoxin in Apaches in Whiteriver, Arizona.

Authors:  R B Sack; N Hirschborn; W E Woodward; D A Sack; R A Cash
Journal:  Infect Immun       Date:  1975-12       Impact factor: 3.441

5.  Purification of the polymyxin-released, heat-labile enterotoxin of Escherichia coli.

Authors:  D J Evans; D G Evans; S H Richardson; S L Gorbach
Journal:  J Infect Dis       Date:  1976-03       Impact factor: 5.226

6.  Mechanism of activation adenylate cyclase in vitro by polymyxin-released, heat-labile enterotoxin of Escherichia coli.

Authors:  D M Gill; D J Evan; D G Evans
Journal:  J Infect Dis       Date:  1976-03       Impact factor: 5.226

7.  Clinical cholera caused by enterotoxigenic Escherichia coli.

Authors:  R A Finkelstein; M L Vasil; J R Jones; R A Anderson; T Barnard
Journal:  J Clin Microbiol       Date:  1976-03       Impact factor: 5.948

8.  Travelers' diarrhea in Mexico. A prospective study of physicians and family members attending a congress.

Authors:  M H Merson; G K Morris; D A Sack; J G Wells; J C Feeley; R B Sack; W B Creech; A Z Kapikian; E J Gangarosa
Journal:  N Engl J Med       Date:  1976-06-10       Impact factor: 91.245

9.  Immunization with Escherichia coli enterotoxin protects against homologous enterotoxin challenge.

Authors:  R B Sack
Journal:  Infect Immun       Date:  1973-10       Impact factor: 3.441

10.  Differences in the response of rabbit small intestine to heat-labile and heat-stable enterotoxins of Escherichia coli.

Authors:  D G Evans; D J Evans; N F Pierce
Journal:  Infect Immun       Date:  1973-06       Impact factor: 3.441

View more
  9 in total

1.  Enterotoxigenic Escherichia coli elicits immune responses to multiple surface proteins.

Authors:  Koushik Roy; Scott Bartels; Firdausi Qadri; James M Fleckenstein
Journal:  Infect Immun       Date:  2010-05-10       Impact factor: 3.441

2.  Solid-phase microtiter radioimmunoassay blocking test for detection of antibodies to Escherichia coli heat-labile enterotoxin.

Authors:  H B Greenberg; M M Levine; M H Merson; R B Sack; D A Sack; J R Valdesuso; D Nalin; D Hoover; R M Chanock; A Z Kapikian
Journal:  J Clin Microbiol       Date:  1979-01       Impact factor: 5.948

3.  Differences in serological responses and excretion patterns of volunteers challenged with enterotoxigenic Escherichia coli with and without the colonization factor antigen.

Authors:  D G Evans; T K Satterwhite; D J Evans; H L DuPont
Journal:  Infect Immun       Date:  1978-03       Impact factor: 3.441

Review 4.  Pathophysiological effects of Vibrio cholerae and enterotoxigenic Escherichia coli and their exotoxins on eucaryotic cells.

Authors:  K L Richards; S D Douglas
Journal:  Microbiol Rev       Date:  1978-09

5.  Emporiatric enteritis: lessons learned from U.S. students in Mexico.

Authors:  H L Dupont; C D Ericsson; M W Dupont
Journal:  Trans Am Clin Climatol Assoc       Date:  1986

6.  Protective effect of active immunization with purified Escherichia coli heat-labile enterotoxin in rats.

Authors:  F A Klipstein; R F Engert
Journal:  Infect Immun       Date:  1979-03       Impact factor: 3.441

7.  Incidence of bacterial enteropathogens in foods from Mexico.

Authors:  L V Wood; L E Ferguson; P Hogan; D Thurman; D R Morgan; H L DuPont; C D Ericsson
Journal:  Appl Environ Microbiol       Date:  1983-08       Impact factor: 4.792

8.  Protective effect of immunization with heat-labile enterotoxin in gnotobiotic rats monocontaminated with enterotoxigenic Escherichia coli.

Authors:  F A Klipstein; R F Engert; H B Short
Journal:  Infect Immun       Date:  1980-04       Impact factor: 3.441

9.  Enzyme-linked immunosorbent assay to measure antibodies to purified heat-labile enterotoxins from human and porcine strains of Escherichia coli and to cholera toxin: application in serodiagnosis and seroepidemiology.

Authors:  M M Levine; C R Young; R E Black; Y Takeda; R A Finkelstein
Journal:  J Clin Microbiol       Date:  1985-02       Impact factor: 5.948

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.